Quick Answer
Compass Therapeutics, Inc. reported Total Assets of $219.59 million for the year ending 2025.
- Compass Therapeutics, Inc. showed an increase of +56.4% in Total Assets from 2024 to 2025.
- This data is from Compass Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2018 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2018: $7.2 thousand | Q3 2018: $2.4 thousand | Q4 2018: $4.7 thousand | Q2 2019: $4.9 thousand | Q3 2019: $882.00 | Q2 2020: $70.45 million | Q3 2020: $60.69 million | Q1 2021: $48.20 million | Q2 2021: $40.87 million | Q3 2021: $34.90 million | Q1 2022: $146.56 million | Q2 2022: $140.26 million | Q3 2022: $127.84 million | Q1 2023: $187.98 million | Q2 2023: $179.18 million | Q3 2023: $170.04 million | Q1 2024: $161.14 million | Q2 2024: $155.61 million | Q3 2024: $149.15 million | Q1 2025: $131.45 million | Q2 2025: $116.70 million | Q3 2025: $231.26 million.
- Over the full 10 years of available data (2018 to 2025), Compass Therapeutics, Inc.'s Total Assets has grown by 878,351,900.0%.
- Historical annual values: Fiscal year 2025: $219.59 million | Fiscal year 2024: $140.40 million | Fiscal year 2023: $156.88 million | Fiscal year 2022: $199.65 million | Fiscal year 2021: $153.76 million | Fiscal year 2020: $51.91 million | Fiscal year 2020: $3.7 thousand | Fiscal year 2019: $30.38 million | Fiscal year 2019: $4.9 thousand | Fiscal year 2018: $25.00.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: